| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | n/a | n/a |
| Intrinsic value (DCF) | n/a | |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) is a clinical-stage biotechnology company pioneering novel therapies for hematopoietic stem cell transplantation and gene therapies. Headquartered in Redwood City, California, Jasper focuses on developing briquilimab, a first-in-class monoclonal antibody designed to condition patients for stem cell transplants by clearing hematopoietic stem cells from bone marrow. The company targets critical unmet needs in chronic spontaneous urticaria, myelodysplastic syndrome, and gene-edited stem cell grafts. With no approved products yet, Jasper is strategically positioned in the high-growth cell and gene therapy market, leveraging its proprietary platform to enhance transplant efficacy and safety. Its innovative approach could disrupt the $10B+ stem cell transplantation market, offering potential long-term value for investors in the evolving biotech landscape.
Jasper Therapeutics presents a high-risk, high-reward opportunity for investors. As a pre-revenue company with a market cap of ~$1.5M, its value hinges on clinical success of briquilimab and stem cell engineering platforms. The 2.756 beta reflects extreme volatility typical of developmental biotech stocks. While $71.6M in cash provides runway, the $71.3M net loss underscores burn rate risks. Investment appeal lies in the novel mechanism of briquilimab—if proven effective, it could capture share in stem cell conditioning ($1.4B market by 2027) and gene therapy prep. However, competition from established players like Magenta Therapeutics and lack of near-term catalysts warrant caution. Suitable only for speculative investors comfortable with binary clinical trial outcomes.
Jasper's competitive edge stems from briquilimab's unique CD117-targeting mechanism, potentially offering safer conditioning than chemotherapy or radiation-based regimens. Unlike legacy approaches that cause organ toxicity, briquilimab aims for precise stem cell clearance—a differentiation critical in gene therapy where conditioning toxicity limits patient eligibility. The company's focus on stem cell graft engineering also addresses key limitations in allogeneic transplants (graft rejection) and autologous therapies (low cell persistence). However, Jasper faces significant challenges: 1) Late-stage competitors like Sanofi (anti-CD52 antibody Lemtrada) dominate conditioning markets, 2) Emerging CRISPR-based conditioning (e.g., Graphite Bio) could leapfrog antibody approaches, and 3) Limited pipeline depth beyond briquilimab increases dependency on a single asset. Jasper's $71.6M cash position trails larger peers, constraining trial scalability. Success hinges on demonstrating superior patient outcomes in ongoing trials for myelodysplastic syndrome (NCT05457440) and establishing partnerships to offset funding gaps.